Compare LC & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LC | HROW |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2008 | N/A |
| Metric | LC | HROW |
|---|---|---|
| Price | $17.12 | $41.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $22.64 | ★ $69.86 |
| AVG Volume (30 Days) | ★ 2.5M | 437.6K |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $314,702,000.00 | N/A |
| Revenue This Year | N/A | $31.62 |
| Revenue Next Year | $14.35 | $50.77 |
| P/E Ratio | $14.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.78 | $21.18 |
| 52 Week High | $21.67 | $54.98 |
| Indicator | LC | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 59.33 | 59.34 |
| Support Level | $16.80 | $40.61 |
| Resistance Level | $17.41 | $41.65 |
| Average True Range (ATR) | 0.83 | 1.63 |
| MACD | -0.00 | 0.33 |
| Stochastic Oscillator | 45.43 | 81.88 |
LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.